Inhibrx Biosciences, Inc. (NASDAQ: INBX - Get Free Report) Director Jon Kayyem purchased 5,000 share

The purchase of 25,000 shares for ~$2.6 million was executed at a weighted average price of $105.82

Inhibrx Biosciences (INBX) maintains a "Strong Buy" rating, driven by major clinical and regulatory

Inhibrx (INBX) advances ozekibart and INBRX-106, targeting rare cancers and large immuno-oncology ma

Inhibrx Biosciences Inc. (NASDAQ:INBX) announced primary endpoint results from the randomized Phase

Inhibrx Biosciences reports Phase 2 HexAgon trial data showing improved response rates for INBRX-106

Inhibrx Biosciences said on Tuesday its experimental combination cancer drug helped reduce tumors in

First OX40 agonist to demonstrate clinical benefit in a randomized study INBRX-106 plus pembrolizuma

– Event to be webcast live on Tuesday, September 8 th at 5:00 a.m. PT –SAN DIEGO, Sept. 4, 2026 /PRN

– Event to be webcast live on Tuesday, September 8 th at 5:00 a.m. PT – SAN DIEGO, Sept.

HC Wainwright & Co. analyst Robert Burns initiates coverage on Inhibrx Biosciences (NASDAQ:IN

SAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the

Inhibrx is transitioning from a platform to a clinical-stage biotech, with ozekibart and INBRX-106 a

SAN DIEGO, July 16, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. ("Inhibrx" or the "Company") (Nas

Does Inhibrx Biosciences, Inc. (INBX) have what it takes to be a top stock pick for momentum investo

No filing review issues identified by FDA with PDUFA goal date set for April 14, 2027If Approved, Oz

No filing review issues identified by FDA with PDUFA goal date set for April 14, 2027 If Approved, O

Inhibrx Biosciences (NASDAQ:INBX) reported quarterly losses of $(2.15) per share which missed the an

SAN DIEGO, May 14, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "

Inhibrx Biosciences, Inc. (NASDAQ:INBX) shares are trading higher on Monday as the company is report

Inhibrx Biosciences shares rise after Phase 2 INBRX-106 and Keytruda data showed stronger response r

Inhibrx Biosciences NASDAQ: INBX reported interim randomized Phase 2 data for INBRX-106 in combinati

Today, the Company presented preliminary data from 53 patients (25 in the INBRX-106 combination arm

Interim analyses show INBRX-106 + pembrolizumab achieved a 44.0% confirmed Objective Response Rate (

– Event to be webcast live on Monday, May 11, 2026, at 5:30 a.m. PT –SAN DIEGO, May 8, 2026 /PRNewsw

– Event to be webcast live on Monday, May 11, 2026, at 5:30 a.m. PT – SAN DIEGO, May 8, 2026 /PRNews

Inhibrx Biosciences stock surges after phase I/II CRC data of ozekibart show strong response rates a

Inhibrx Biosciences, Inc. has surged nearly 40% amid rumors of Big Pharma interest in joint spinoffs

Inhibrx explores spin-off of INBRX-106 amid Big Pharma interest, with potential valuation exceeding

U.S. stocks were higher, with the Dow Jones gaining over 350 points on Wednesday. GE Vernova shares

US stocks rise, with Dow gaining over 400 points. Dow up 0.87%, NASDAQ up 0.70%, S&P 500 up 0.69

https://www.reuters.com/world/merck-rivals-eye-deal-inhibrx-experimental-cancer-drug-tied-keytruda-s

Inhibrx plans to meet with the U.S. Food and Drug Administration (FDA) in the second half of 2026 to

Top Wall Street analysts changed outlook on top names. See complete rating changes, including upgrad

Stifel analyst Dara Azar initiates coverage on Inhibrx Biosciences (NASDAQ:INBX) with a Buy ratin

Wall Street surged to fresh all-time highs Friday as a softer-than-expected inflation reading streng

Gainers Axcella Health Inc. (NASDAQ: AXLA) shares climbed 196% to $0.3335 after the company anno

Gainers Golden Sun Education Group Limited (NASDAQ: GSUN) shares surged 92.1% to settle at $52.89